Our Company
Our mission is to change the standard of care for patients with immunologic diseases. We are developing multiple novel biologic molecules toward this end.
Our lead clinical candidate is atacicept:
- A fusion protein that inhibits B cells and plasma cells, which can produce disease-causing antibodies
- Potential best-in-class disease-modifying treatment for IgA Nephropathy (IgAN), an autoimmune disease that often leads to kidney failure and has few treatment options
- In ORIGIN, a Phase 2b clinical trial for IgAN, atacicept met the primary endpoint at 24 weeks and key secondary endpoints at 36 weeks for improved kidney function
- ORIGIN 3, a pivotal Phase 3 clinical trial, initiated June 2023
- Target profile: self-administered subcutaneously once weekly
We are also developing MAU868:
- A monoclonal antibody that neutralizes infection by blocking BK virus (BKV) binding to host cells
- In a Phase 2 clinical trial for treatment of BK viremia in kidney transplant patients
- No BKV-specific treatment currently available
- Target profile: monthly IV administration